| Females, n (%) |
15 (71.4) |
17 (81) |
|
| Males, n (%) |
6 (28.6) |
4 (19) |
|
| Age, y (median) |
57 (20–77) |
44 (26–69) |
|
| Smokers, n (%) |
9 (42.8) |
3 (14.3) |
|
| Duration GD, month (median) |
14 (3–108) |
21 (10–35) |
0.018 |
| TRAb, lU/L (reference range, <1.8) |
19.9 (3.7–156.4) |
<0.9 (<0.9–4.9) |
<0.001 |
| Radioiodine treatment, n (%) |
5 (23.8) |
0 (0) |
0.019 |
| Thyroid surgery, n (%) |
1 (4.8) |
1 (4.8) |
1 |
| TSH, mlU/L (median; reference range, 0.5–3.6) |
0.05 (0.01–1.7) |
0.88 (0.03–4.34) |
<0.001 |
| Serum FT4, pmol/L (reference range, 8–21) |
17.3 (10.1–49.2) |
13.5 (11.4–21.3) |
0.004 |
| Serum FT3, pmol/L (reference range, 3.6–8.3) |
7.4 (4.4–20.0) |
5.4 (4.5–8.6) |
0.005 |
